Business Context and Reporting Period
Company: Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
Filing Type: Form 8-K (Current Report)
Date of Report: August 8, 2024 (Event Date)
Reporting Period: Specific event reporting; not a periodic financial report.
Business Context: The Company is an emerging growth company focused on the development of Ropidoxuridine, a radiation-sensitizing agent for the treatment of glioblastoma.
Key Financial Metrics
This filing does not contain comprehensive financial statements, revenue, profit, cash flow, or margin data. The only specific financial metric disclosed relates to a new contractual obligation:
- New Contractual Commitment: Approximately $2.3 million payable in stages to Theradex Systems, Inc. (CRO) for a 53-month term to oversee a Phase 2 clinical trial.
- Liquidity/Debt: The filing text does not provide a clear value for current cash balances, debt levels, or liquidity positions.
Material Changes and Events
The primary material change reported is the execution of a definitive agreement to advance clinical development:
- Item 1.01 (Material Definitive Agreement): On August 8, 2024, Shuttle Pharmaceuticals, Inc. (subsidiary) entered into a Work Order with Theradex Systems, Inc. to manage the Phase 2 study of Ropidoxuridine for IDH-Wildtype Glioblastoma with unmethylated MGMT Promoter.
- Study Status: The trial was FDA-approved in January 2024 and IRB-approved on June 21, 2024. The Company is signing up six clinical sites; two have completed initial visits, and one is ready to enroll patients.
- Intellectual Property: The agreement ensures Shuttle Pharma retains ownership of all IP developed during the trial.
- Item 8.01 (Other Events): On August 14, 2024, the Company announced agreements with two of the six planned clinical trial locations.
- Forward-Looking Statements: The filing contains forward-looking statements regarding future results, strategy, and plans. Actual results may differ materially due to known and unknown risks.
- Clinical Trial Risks: Success depends on the ability to enroll patients, the performance of the CRO, and regulatory outcomes, none of which are guaranteed.
- Financial Impact: The $2.3 million fee represents a future cash outflow contingent on services performed over 53 months.
- Verify the Company's current cash position and ability to fund the $2.3 million CRO fee and ongoing operational costs.
- Monitor the progress of patient enrollment at the six planned clinical sites.
- Review the full text of the Work Order (Exhibit 10.1) and Master Services Agreement (Exhibit 10.2) for specific payment milestones and termination clauses.
- Track regulatory updates regarding the Phase 2 study of Ropidoxuridine for glioblastoma.
Guidance, Outlook, and Risks
Outlook: Management is actively progressing the Phase 2 clinical trial, with site initiation underway and patient enrollment anticipated to begin soon at the first ready site.
Risks and Contingencies: